The observed positive effects of ALM16 against hepatic steatosis and liver damage were, at least partly, shown to be mediated by the downregulation of SREBP-1c and FAS expression and upregulation of CPT-1 expression, through the modulation of AMPK and ACC signaling, in the established NAFLD in vivo model. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.